Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag plus standard immunosuppression in treatment‑naive severe aplastic anemia
2017-004364-35Phase 2
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eltrombopag in aplastic anemia, sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Primary safety and activity endpoint.
02
Drugs
eltrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on 2017-004364-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004364-35.